Buying Plus Therapeutics stock in 2026: price, dividend and analysis

Are you interested in Plus Therapeutics stock? Mind the name change: the Californian company now operates under the Cerenome identity. This independent sheet gathers the price, the presentation of the rhenium radiotherapy programme, the last fiscal years’ results, the dividend policy, the file’s strengths and risks, then the buying method from France.

Plus Therapeutics stock price

The price is available live from your broker or on the reference financial platforms: the line changed its symbol with the name change, the historical PSTV symbol no longer always pointing to the stock. The capitalisation is very small and liquidity limited; session hours are indicated below.

Plus Therapeutics stock profile

CompanyCerenome, Inc. (formerly Plus Therapeutics, Inc.)
MarketNASDAQ (New York) (checked on 10/11/2026)
Ticker / SymbolHistorical symbol PSTV; new name Cerenome after the change
ISINUS72941H8060
HeadquartersAustin, Texas (United States)
SectorBiotechnology: targeted internal radiotherapy in central-nervous-system oncology
Founded1996
EmployeesAbout 30 staff
Quotation currencyUS dollar (USD)
Fiscal year end31 December
PEA eligibilityNo (issuer domiciled outside the EU/EEA: United States)

Plus Therapeutics presentation: activity and programmes

Rhenium-186 internal radiotherapy

The flagship programme, rhenium obisbemeda, is a targeted radiotherapy administered directly into the central nervous system, developed for serious brain cancers: recurrent glioblastoma, leptomeningeal metastases and paediatric brain tumours. The goal is to deliver a high radiation dose to the tumour while sparing healthy tissues, where classic therapeutic options are exhausted.

A portfolio extended to liver cancers and diagnostics

The rhenium-188 NanoLiposome platform is studied by intra-arterial injection for primary and secondary liver cancers. The company also develops laboratory tests, including the CNSide Test, which identifies metastatic tumour cells in central-nervous-system fluid, as well as a data-analysis platform dedicated to precision oncology.

A name change to integrate

The company announced its evolution under the Cerenome name, with a new listing symbol: the old PSTV references overlap in databases during the transition. Chief executive Marc Hedrick leads this reorganisation, accompanied by tight expense management after several years of heavy cash consumption.

Plus Therapeutics results and financial data

Consolidated accounts of the last three fiscal years ended 31 December:

IndicatorFY 2023FY 2024FY 2025One-year change
Revenue$4.9m$5.8m$5.2m-10.6%
Net income-$13.3m-$13.0m-$22.4mwidening loss

Amounts in millions of dollars. Source: S&P Global Market Intelligence via StockAnalysis, consolidated accounts; data consulted on 10/11/2026.

Revenues come essentially from laboratory-test and research-service activities, not from the drug: they remain below clinical and administrative spending. The net loss widened in 2025, a sign that financing the phase studies remains the main budget item; cash and capital raises condition the continuation of the programmes.

Tableau originalDiversifiez votre patrimoineInvestissez dans l’artDes tableaux originaux, pièces uniques signées par l’artiste. Un actif tangible, loin des écrans et des cotations.Voir les tableaux →

Plus Therapeutics stock dividend

Plus Therapeutics pays no dividend and cannot pay one: the company records annual losses and devotes its resources to clinical trials. No current yield is expected on this type of stock.

Performance rests entirely on the pipeline’s potential valuation: a phase success, a licensing agreement or a buyout by a large laboratory are the classic triggers; a dilutive capital increase remains the permanent symmetrical risk.

Should You Buy Plus Therapeutics Stock in 2026?

Strengths:

  • Rare positioning in targeted internal radiotherapy of the central nervous system, a field of unmet medical needs.
  • Diversified portfolio: brain oncology, liver, revenue-generating diagnostic laboratory tests.
  • Name change and reorganisation signalling a strategic refocusing.

Points to watch:

  • Micro-capitalisation with very low liquidity: high volatility and wide bid-ask spread.
  • Rising net losses ($22.4m in 2025) and continuous dependence on dilutive fundraisings.
  • Early-stage programmes: possible clinical failure, regulatory delay or listing-compliance issue.

This stock belongs to the very-small-cap speculative biotech category: a position must remain marginal and assumed as a clinical bet, not a wealth investment. To compare stocks with more varied risk profiles, see our selection of the best stocks.

Fundamental and technical analysis of Plus Therapeutics stock

Fundamental analysis

The follow-up focuses on three points: net cash relative to the consumption rate, patient recruitment in the rhenium obisbemeda studies, and laboratory-test revenues that amortise the research. The 2023-2025 trajectory shows scarcity management: every quarter without outside financing reduces the room for manoeuvre.

Technical analysis

The stock trades within the NASDAQ but on low volumes: movements concentrate around study announcements, scientific publications and financial operations. Reference levels are read at the twelve-month extremes; limit orders are essential to avoid unfavourable executions.

How to buy Plus Therapeutics stock?

  1. Choose a broker giving access to the NASDAQ; compare fees in our comparison of the best stock brokers.
  2. Open an ordinary securities account (the PEA is excluded for an American stock) and have your identity verified.
  3. Fund the account taking dollar-euro conversion fees into account.
  4. Place the order on the symbol in force after the name change — check the symbol displayed by your broker before confirming.

Trading hours

The NASDAQ trades from 9:30 am to 4:00 pm New York time, i.e. generally 3:30 pm to 10:00 pm in Paris. Stocks are bought per unit and the W-8BEN form reduces the American withholding at the source.

Taxation

On a securities account, capital gains fall under the French 30% single flat levy; no dividend being paid, taxation is limited to sales and to any tax credit linked to foreign losses. (Non-French readers: check your own jurisdiction’s rules.)

Frequently asked questions about Plus Therapeutics stock

Are Plus Therapeutics and Cerenome the same company?

Yes. Plus Therapeutics changed its name to become Cerenome; databases display the new identity, with a transition period on the symbols.

On which exchange is the stock listed?

On the NASDAQ in the United States, in dollars. The capitalisation is very small and liquidity limited.

Can this stock go in a PEA?

No. The issuer is domiciled in the United States, outside the European Union: the stock is held in an ordinary securities account.

What is the company’s ISIN code?

US72941H8060.

What are Plus Therapeutics’ 2025 results?

Revenue of $5.2 million, essentially test and service revenues, and a net loss of $22.4 million, according to the consolidated accounts.

Disclaimer: this content is informational and does not constitute investment advice. Investing in the stock market carries a risk of capital loss; past performance is not indicative of future performance.

Suivez-nous sur Telegram